RESUMEN
N-linked glycosylation is a crucial post-translational modification involved in protein folding, function, and clearance. N-linked glycosylation is also used therapeutically to enhance the half-lives of many proteins. Antithrombin, a serpin with four potential N-glycosylation sites, plays a pivotal role in hemostasis, wherein its deficiency significantly increases thrombotic risk. In this study, we used the introduction of N-glycosylation sites as a tool to explore what effect this glycosylation has on the protein folding, secretion, and function of this key anticoagulant. To accomplish this task, we introduced an additional N-glycosylation sequence in each strand. Interestingly, all regions that likely fold rapidly or were surrounded by lysines were not glycosylated even though an N-glycosylation sequon was present. The new sequon in the strands of the A- and B-sheets reduced secretion, and the B-sheet was more sensitive to these changes. However, the mutations in the strands of the C-sheet allowed correct folding and secretion, which resulted in functional variants. Therefore, our study revealed crucial regions for antithrombin secretion and could potentially apply to all serpins. These results could also help us understand the functional effects of natural variants causing type-I deficiencies.
Asunto(s)
Proteínas Antitrombina/química , Proteínas Antitrombina/metabolismo , Conformación Proteica , Procesamiento Proteico-Postraduccional , Antitrombina III/química , Antitrombina III/genética , Antitrombina III/metabolismo , Proteínas Antitrombina/genética , Dicroismo Circular , Glicosilación , Humanos , Modelos Moleculares , Proteínas Mutantes/química , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Mutación , TrombosisRESUMEN
OBJECTIVE: Thrombin, platelets, and plasmin are three key factors involved in hemostasis and thrombolysis. Thrombolytic therapy with clinically approved drugs is often followed by recurrent thrombosis caused by thrombin-induced platelet aggregation from the clot debris. In order to minimize these problems, new constructs were designed for the expression of recombinant staphylokinase (rSAK) and also a fusion protein composed of staphylokinase, 20 amino acids containing 2 RGD followed by tsetse thrombin Inhibitor (SAK-2RGD-TTI) in Pichia pastoris. RESULT: Modeling the tertiary structure of SAK-2RGD-TTI showed that the linker containing RGD and TTI did not interfere with proper folding of SAK. In laboratory testing, the purified SAK-2RGD-TTI (420 µg/mL) dissolved an average of 45% of the blood clot. The activity of the SAK-2RGD-TTI was also confirmed in various tests including human plasminogen activation assay, fibrin clot lysis assay, well diffusion method, activated partial thromboplastin time and platelet rich clot lysis assay. CONCLUSION: Our findings suggest that SAK-2RGD-TTI has improved therapeutic properties preventing reocclussion. It further confirms that it is practicable to assemble and produce a hybrid multifunctional protein that targets hemostatic process at various stages.
Asunto(s)
Metaloendopeptidasas/metabolismo , Pichia/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Terapia Trombolítica/métodos , Proteínas Antitrombina/química , Proteínas Antitrombina/genética , Proteínas Antitrombina/metabolismo , Humanos , Proteínas de Insectos/química , Proteínas de Insectos/genética , Proteínas de Insectos/metabolismo , Metaloendopeptidasas/química , Metaloendopeptidasas/genética , Simulación de Dinámica Molecular , Oligopéptidos/química , Oligopéptidos/genética , Oligopéptidos/metabolismo , Pichia/genética , Conformación Proteica , Proteínas Recombinantes de Fusión/genéticaRESUMEN
Inherited antithrombin (AT) deficiency is one of the most clinically significant forms of congenital thrombophilia and follows an autosomal dominant mode of inheritance. We analyzed SERPINC1 in a patient who developed deep-vein thrombosis and low AT activity during pregnancy, and identified a novel missense mutation c.259A>G (p.Asn87Asp; N87D). Surprisingly, analysis of the parents' DNA showed that they did not possess this mutant, and thus, it may have been due to a de novo mutation. We also expressed this mutant AT protein in COS-1 cells and compared its intracellular localization and intracellular and extracellular antigen levels with that of wild-type AT. The expression experiment did not reveal a significant difference in the antigen levels of the mutant and wild-type AT in the cell lysate, but the mutant AT antigen level was markedly lower than that of its wild-type counterpart in the COS-1 cell supernatant. Immunofluorescence did not indicate any difference between the mutant and wild-type AT in terms of cytoplasmic localization of fluorescence signals. Our findings suggest that the patient's AT deficiency may have been caused by impaired extracellular secretion of mutant AT protein p.Asn87Asp.
Asunto(s)
Antígenos/metabolismo , Deficiencia de Antitrombina III/genética , Antitrombina III/genética , Proteínas Antitrombina/genética , Proteínas Antitrombina/fisiología , Mutación Missense , Complicaciones del Embarazo/genética , Adulto , Animales , Proteínas Antitrombina/inmunología , Proteínas Antitrombina/metabolismo , Células COS , Chlorocebus aethiops , Femenino , Humanos , Embarazo , Trombofilia/genética , Trombosis de la VenaRESUMEN
Antithrombin mainly inhibits factor Xa and thrombin. The reactive center loop (RCL) is crucial for its interactions with its protease targets and is fully inserted into the A-sheet after its cleavage, causing translocation of the covalently linked protease to the opposite end of the A-sheet. Antithrombin variants with altered RCL hinge residues behave as substrates rather than inhibitors, resulting in stoichiometries of inhibition greater than one. Other antithrombin residues have been suggested to interfere with RCL insertion or the stability of the antithrombin-protease complex, but available crystal structures or mutagenesis studies have failed to identify such residues. Here, we characterized two mutations, S365L and I207T, present in individuals with type II antithrombin deficiency and identified a new antithrombin functional domain. S365L did not form stable complexes with thrombin or factor Xa, and the I207T/I207A variants inhibited both proteases with elevated stoichiometries of inhibition. Close proximity of Ile-207 and Ser-365 to the inserted RCL suggested that the preferred reaction of these mutants as protease substrates reflects an effect on the rate of the RCL insertion and protease translocation. However, both residues lie within the final docking site for the protease in the antithrombin-protease complex, supporting the idea that the enhanced substrate reactions may result from an increased dissociation of the final complexes. Our findings demonstrate that the distal end of the antithrombin A-sheet is crucial for the last steps of protease inhibition either by affecting the rate of RCL insertion or through critical interactions with proteases at the end of the A-sheet.
Asunto(s)
Proteínas Antitrombina/química , Trastornos de la Coagulación Sanguínea Heredados , Factor Xa/química , Simulación del Acoplamiento Molecular , Trombina/química , Sustitución de Aminoácidos , Proteínas Antitrombina/genética , Proteínas Antitrombina/metabolismo , Dominio Catalítico , Factor Xa/genética , Factor Xa/metabolismo , Femenino , Humanos , Masculino , Mutación Missense , Dominios Proteicos , Estructura Secundaria de Proteína , Trombina/genética , Trombina/metabolismoRESUMEN
Existing evidence suggests that in most cases antithrombin deficiency can be explained by mutations in its gene, SERPINC1. We investigated the molecular background of antithrombin deficiency in a single centre family cohort study. We included a total of 21 families comprising 15 original probands and sixty-six relatives, 6 of who were surrogate probands for the genetic analysis. Antithrombin activity and antigen levels were measured. The heparin-antithrombin binding ratio assay was used to distinguish between the different subtypes of type II antithrombin deficiency. SERPINC1 mutations were detected by direct sequencing of all 7 exons and regulatory regions, and multiplex ligation-dependent probe amplification. Eighty-six per cent of the families had a detrimental SERPINC1 gene mutation that segregated in the family. We detected 13 different SERPINC1 gene mutations of which 5 were novel. Among all these mutations, 44% was associated with type I deficiency, whereas the remainder was associated with type II heparin binding site (11%), type II pleiotropic effect (33%), type II reactive site (6%) or had the antithrombin Cambridge II mutation (6%). The current study reports several novel SERPINC1 mutations, thereby adding to our knowledge of the molecular background of antithrombin deficiency. Finally, our results point out the importance of future research outside the conventional SERPINC1 gene approach.
Asunto(s)
Deficiencia de Antitrombina III/genética , Antitrombina III/genética , Mutación/genética , Adolescente , Adulto , Anciano , Proteínas Antitrombina/genética , Preescolar , ADN Recombinante/genética , Exones/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mutación Missense/genética , Linaje , Adulto JovenRESUMEN
We summarize causative genetic mutations for antithrombin (AT) deficiency and their clinical background in Japanese patients. A total of 19 mutations, including seven novel mutations, were identified. We also summarize clinical symptoms of thrombosis, age at onset, family history, and contributing factors for thrombosis, and review the use of prophylactic anticoagulation in pregnant women with heterozygous type II heparin binding site defects (HBS) AT deficiency. The prevalence of thrombosis in probands with type I AT deficiency (88%) was double that observed in those with type II AT deficiency (50%). The prevalence of thrombotic episodes among family members was also higher for type I AT deficiency subjects (82%) than for those with type II AT deficiency (0%). The most common contributing factor for thrombosis among women with type I AT deficiency was pregnancy. Forty-five percent of women with type I AT deficiency developed thrombotic events before the 20th week of gestation. In contrast, women with type II (HBS) AT deficiency appear to be at a lower risk of thrombosis during pregnancy. In conclusion, thrombotic risk varies among different subtypes. Risk assessments based on genetic/clinical backgrounds may contribute to appropriate diagnosis, treatment, and prophylaxis for patients with AT deficiency.
Asunto(s)
Proteínas Antitrombina/deficiencia , Mutación/fisiología , Adolescente , Adulto , Anciano , Proteínas Antitrombina/genética , Pueblo Asiatico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Embarazo , Complicaciones Cardiovasculares del Embarazo/diagnóstico , Factores de Riesgo , Trombofilia/complicaciones , Trombofilia/diagnóstico , Trombosis/etiologíaRESUMEN
Venous thromboembolism (VTE) occurs frequently in pregnant women and is a significant cause of maternal death. Hemostatic abnormalities were examined in 18 pregnant women with thrombosis. We studied five families with congenital antithrombin (AT) deficiency, and two families with congenital protein C (PC) deficiency. One woman with PC deficiency showed protein S (PS) Tokushima. The AT activity levels were significantly lower at the onset of thrombosis in the pregnant women than during the stable state. The PS activity and antigen levels were also significantly lower at the onset of thrombosis. In the patients with congenital AT deficiency, AT activity was significantly low in the stable state and decreased further at the onset of thrombosis. Although AT levels were normal before pregnancy, they subsequently decreased and in two cases the patients required the administration of AT after pregnancy. Gene analysis revealed one family with AT Budapest, one family with AT Toyama, and three families with AT Glasgow. Additionally, there were one family with PC Tochigi and one family with combined heterozygous of PC deficiency and PS Tokushima. In conclusion, the deficiency of natural anticoagulants, especially AT, is an important cause of pregnancy-related VTE.
Asunto(s)
Antitrombinas/metabolismo , Complicaciones Cardiovasculares del Embarazo/sangre , Deficiencia de Proteína C/sangre , Tromboembolia Venosa/sangre , Adulto , Anciano , Anciano de 80 o más Años , Proteínas Antitrombina/genética , Proteínas Antitrombina/metabolismo , Femenino , Humanos , Masculino , Embarazo , Complicaciones Cardiovasculares del Embarazo/genética , Deficiencia de Proteína C/genética , Tromboembolia Venosa/genéticaRESUMEN
Antithrombin inhibits blood coagulation through the interaction with serine proteases in both intrinsic and extrinsic pathways. In addition, antithrombin also shows anti-inflammatory properties, which are independent of its effects on coagulation. This work shows for the first time the cloning and sequencing of antithrombin from a snake species. This predicted protein is composed by 430 amino acids and presents about 64.5% sequence identity to human antithrombin. Biacore experiments revealed that the binding affinity of Bothrops jararaca snake antithrombin to heparin was ~30 times higher than that of human antithrombin. Furthermore, Bothrops jararaca antithrombin is more effective in preventing acute inflammation induced by carrageenan when compared to human antithrombin. Hence, the results showed herein suggest that Bothrops jararaca antithrombin can play a key role in the control of acute inflammation and that this molecule might be used as a pharmacological tool and as a prototype for drug development.
Asunto(s)
Antiinflamatorios/uso terapéutico , Proteínas Antitrombina/uso terapéutico , Bothrops/genética , Inflamación/tratamiento farmacológico , Proteínas de Reptiles/uso terapéutico , Secuencia de Aminoácidos , Animales , Antiinflamatorios/química , Antiinflamatorios/metabolismo , Proteínas Antitrombina/química , Proteínas Antitrombina/genética , Carragenina , Clonación Molecular , Edema/inducido químicamente , Edema/tratamiento farmacológico , Humanos , Inflamación/inducido químicamente , Masculino , Ratones , Datos de Secuencia Molecular , Proteínas de Reptiles/química , Proteínas de Reptiles/genética , Alineación de SecuenciaRESUMEN
OBJECTIVE To review studies on the readability of package leaflets of medicinal products for human use. METHODS We conducted a systematic literature review between 2008 and 2013 using the keywords “Readability and Package Leaflet” and “Readability and Package Insert” in the academic search engine Biblioteca do Conhecimento Online, comprising different bibliographic resources/databases. The preferred reporting items for systematic reviews and meta-analyses criteria were applied to prepare the draft of the report. Quantitative and qualitative original studies were included. Opinion or review studies not written in English, Portuguese, Italian, French, or Spanish were excluded. RESULTS We identified 202 studies, of which 180 were excluded and 22 were enrolled [two enrolling healthcare professionals, 10 enrolling other type of participants (including patients), three focused on adverse reactions, and 7 descriptive studies]. The package leaflets presented various readability problems, such as complex and difficult to understand texts, small font size, or few illustrations. The main methods to assess the readability of the package leaflet were usability tests or legibility formulae. Limitations with these methods included reduced number of participants; lack of readability formulas specifically validated for specific languages (e.g., Portuguese); and absence of an assessment on patients literacy, health knowledge, cognitive skills, levels of satisfaction, and opinions. CONCLUSIONS Overall, the package leaflets presented various readability problems. In this review, some methodological limitations were identified, including the participation of a limited number of patients and healthcare professionals, the absence of prior assessments of participant literacy, humor or sense of satisfaction, or the predominance of studies not based on role-plays about the use of medicines. These limitations should be avoided in future ...
OBJECTIVO Analisar a literatura sobre legibilidade das bulas dos medicamentos para uso humano. MÉTODOS Estudo de revisão sistemática, utilizando as palavras-chave “Readability and Package Leaflet” e “Readability and Package Insert”e a ferramenta de busca académica b-on, que contém diferentes bases bibliográficas. O período analisado foi entre 2008 e 2013. Foram aplicados os critérios PRISMA para redigir o relatório da revisão. Foram incluídos artigos originais de pesquisa quantitativa ou qualitativa. Os critérios de exclusão foram: artigos de opinião ou de revisão, ou escritos numa língua diferente do inglês, português, italiano, francês ou espanhol. RESULTADOS Foram identificados 202 trabalhos, dos quais 180 foram excluídos e 22 selecionados para análise: dois com profissionais de saúde, 10 com pacientes, três sobre reações adversas e sete descritivos. As bulas apresentaram diversos problemas de legibilidade, entre os quais: textos insuficientemente claros e simples, utilização de tamanhos de letra pequenos e número reduzido de ilustrações. Os principais métodos utilizados para avaliar a legibilidade das bulas foram as fórmulas e os testes de legibilidade/usabilidade. Entre as limitações metodológicas, foram identificados aspetos como o recurso a amostras pequenas, a inexistência de fórmulas de legibilidade específicas para a língua em causa, e.g., português, e a realização de testes de compreensão em grupos de pacientes sem avaliação prévia da literacia, dos conhecimentos específicos na área da saúde, das capacidades cognitivas, ou do grau de satisfação dos participantes. CONCLUSÕES Em geral, as bulas apresentaram diversos problemas de legibilidade. Adicionalmente, nesta revisão foram identificadas algumas limitações metodológicas nos estudos revistos (e.g. a participação de um número reduzido de pacientes e profissionais de saúde, a ausência da avaliação prévia da literacia, do humor ou satisfação dos participantes ...
Asunto(s)
Animales , Humanos , Factores de Coagulación Sanguínea/farmacología , Factores de Coagulación Sanguínea/uso terapéutico , Hemostasis/efectos de los fármacos , Anticuerpos Monoclonales , Proteínas Antitrombina/genética , Antitrombinas , Biotecnología , Ensayos Clínicos como Asunto , Factor IX , Factor VIII , Factor VIIa , Hemostasis/fisiología , Ingeniería de Proteínas , Interferencia de ARN , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Insuficiencia del Tratamiento , Resultado del TratamientoAsunto(s)
Trombofilia/diagnóstico , Trombofilia/genética , Tromboembolia Venosa/prevención & control , Anticoagulantes/uso terapéutico , Proteínas Antitrombina/genética , Anticonceptivos Hormonales Orales , Contraindicaciones , Enfermedad de la Arteria Coronaria/sangre , Factor V/genética , Femenino , Heterocigoto , Terapia de Reemplazo de Hormonas , Humanos , Mutación , Mutación Missense , Polimorfismo Genético , Embarazo , Complicaciones Hematológicas del Embarazo/prevención & control , Resultado del Embarazo , Protrombina/genética , Púrpura Fulminante/etiología , Recurrencia , Factores de Riesgo , Tromboembolia Venosa/etiologíaRESUMEN
Venous thromboembolism [TE] is a multifactorial disease and antithrombin deficiency [ATD] constitutes a major risk factor. In the present study the prevalence of ATD and the clinical presentation at TE onset in a cohort of paediatric index cases are reported. In 319 unselected paediatric patients (0.1-18 years) from 313 families, recruited between July 1996 and December 2013, a comprehensive thrombophilia screening was performed along with recording of anamnestic data. 21 of 319 paediatric patients (6.6%), corresponding to 16 of 313 families (5.1%), were AT-deficient with confirmed underlying AT gene mutations. Mean age at first TE onset was 14 years (range 0.1 to 17). Thrombotic locations were renal veins (n=2), cerebral veins (n=5), deep veins (DVT) of the leg (n=9), DVT & pulmonary embolism (n=4) and pelvic veins (n=1). ATD co-occurred with the factor-V-Leiden mutation in one and the prothrombin G20210A mutation in two children. In 57.2% of patients a concomitant risk factor for TE was identified, whereas 42.8% of patients developed TE spontaneously. A second TE event within primarily healthy siblings occurred in three of 313 families and a third event among siblings was observed in one family. In an unselected cohort of paediatric patients with symptomatic TE, the prevalence of ATD adjusted for family status was 5.1%. Given its clinical implication for patients and family members, thrombophilia testing should be performed and the benefit of medical or educational interventions should be evaluated in this high risk population.
Asunto(s)
Proteínas Antitrombina/genética , Trombofilia/epidemiología , Tromboembolia Venosa/epidemiología , Adolescente , Niño , Preescolar , Estudios de Cohortes , Factor V/genética , Pruebas Genéticas , Humanos , Lactante , Educación del Paciente como Asunto , Prevalencia , Protrombina/genética , Riesgo , Trombofilia/genética , Tromboembolia Venosa/genéticaRESUMEN
Currently, new clotting factor concentrates are becoming available or are in advanced clinical studies that will significantly improve the treatment of patients with Haemophilia A or Haemophilia B. Various technologies are applied to extend half-life and/or allow for alternative routes of administration, e.g. subcutaneous route. Today, the advances for recombinant factor IX are significantly with half-life extensions to up to 100 h, allowing substitution intervals of 1-2 weeks. For recombinant factor VIII (FVIII) products the effect so far is only moderate, as the half-life extension is limited to about 15-18 h by the clearance of FVIII through its binding to von Willebrand factor. However, novel products applying new technologies with significantly extended half-life are already at the horizont, as a bispecific antibody that mimics FVIII. The pharmacokinetic improvements of the new products will lead to a revision of our current treatment regimens, with regard to intended trough levels, number of tolerated bleeds and likely will drive a greater individualization of regimens. Clearly, the potential of anti drug antibody response for these modified proteins must not be higher than with our current products. Another challenge are the increasingly diverse biochemical characteristics of the new products, that have to be considered when determining potencies and also when monitoring treatment in patients with the various available assays. Despite these challenges, the new products will significantly improve treatment and quality of life for our patients with haemophilia.
Asunto(s)
Factores de Coagulación Sanguínea/farmacología , Factores de Coagulación Sanguínea/uso terapéutico , Hemostasis/efectos de los fármacos , Animales , Anticuerpos Monoclonales , Proteínas Antitrombina/genética , Antitrombinas , Biotecnología , Ensayos Clínicos como Asunto , Factor IX , Factor VIII , Factor VIIa , Hemostasis/fisiología , Humanos , Ingeniería de Proteínas , Interferencia de ARN , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Insuficiencia del Tratamiento , Resultado del TratamientoRESUMEN
Mutations affecting mobile domains of antithrombin induce conformational instability resulting in protein polymerization that associates with a severe clinical phenotype, probably by an unknown gain of function. By homology with other conformational diseases, we speculated that these variants might infect wild-type (WT) monomers reducing the anticoagulant capacity. Infective polymerization of WT polymers and different P1 mutants (p.R425del, p.R425C and p.R425H) were evaluated by using native gels and radiolabeled WT monomers and functional assays. Human embryonic kidney cells expressing the Epstein-Barr nuclear antigen 1 (HEK-EBNA) cells expressing inducible (p.R425del) or two novel constitutive (p.F271S and p.M370T) conformational variants were used to evaluate intracellular and secreted antithrombin under mild stress (pH 6.5 and 39°C for 5 h). We demonstrated the conformational sensitivity of antithrombin London (p.R425del) to form polymers under mild heating. Under these conditions purified antithrombin London recruited WT monomers into growing polymers, reducing the anticoagulant activity. This process was also observed in the plasma of patients with p.R425del, p.R425C and p.R425H mutations. Under moderate stress, coexpression of WT and conformational variants in HEK-EBNA cells increased the intracellular retention of antithrombin and the formation of disulfide-linked polymers, which correlated with impaired secretion and reduction of anticoagulant activity in the medium. Therefore, mutations inducing conformational instability in antithrombin allow its polymerization with the subsequent loss of function, which under stress could sequestrate WT monomers, resulting in a new prothrombotic gain of function, particularly relevant for intracellular antithrombin. The in vitro results suggest a temporal and severe plasma antithrombin deficiency that may contribute to the development of the thrombotic event and to the clinical severity of these mutations.
Asunto(s)
Deficiencia de Antitrombina III/metabolismo , Proteínas Antitrombina/química , Proteínas Antitrombina/metabolismo , Proteínas Mutantes/química , Proteínas Mutantes/metabolismo , Proteínas Antitrombina/genética , Línea Celular , Humanos , Conformación Proteica , Multimerización de Proteína , Estabilidad Proteica , Estrés FisiológicoRESUMEN
Contrary to well-recognized bleeding diathesis in chronic liver disease, thrombotic events can occur in these patients due to reduction or loss of synthesis of anticoagulant proteins. Forty-seven consecutive patients with end-stage liver disease (ESLD) were investigated for activity of protein C, protein S, antithrombin, and factor V Leiden mutation. Forty-two (89.4%) patients had low levels of at least 1 while 33 (70.2%) patients were deficient for all anticoagulant proteins studied. Forty-six (97.9%) patients were negative for factor V Leiden mutation. The deficiencies were more marked in hepatitis C virus-positive patients and patients with model for end-stage liver disease (MELD) score >15. Six (12.8%) patients had portal vein thrombosis (PVT), and all had diminished protein S activity. In conclusions, deficiency of anticoagulant proteins occur in early phase of chronic liver disease. The severity of deficiency is proportional to the severity of liver disease. Despite the high prevalence of hypercoagulability, the incidence of PVT is low. Further studies with larger cohort of patients are needed to support these conclusions and to study other associated factors.
Asunto(s)
Síndrome de Budd-Chiari/epidemiología , Enfermedad Hepática en Estado Terminal/epidemiología , Vena Porta , Trombofilia/epidemiología , Anciano , Proteínas Antitrombina/genética , Proteínas Antitrombina/metabolismo , Síndrome de Budd-Chiari/sangre , Síndrome de Budd-Chiari/complicaciones , Síndrome de Budd-Chiari/genética , Enfermedad Hepática en Estado Terminal/sangre , Enfermedad Hepática en Estado Terminal/complicaciones , Factor V/genética , Factor V/metabolismo , Femenino , Hepatitis C/sangre , Hepatitis C/complicaciones , Hepatitis C/epidemiología , Hepatitis C/genética , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Proteína C/genética , Proteína C/metabolismo , Proteína S/genética , Proteína S/metabolismo , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Trombofilia/sangre , Trombofilia/complicaciones , Trombofilia/genéticaRESUMEN
Deficiencies of antithrombin (AT), protein C (PC) and protein S (PS) or an impaired PC anticoagulant pathway increase the risk of venous thrombosis (VT). By conducting a genome-wide association study (GWAS) on two independent samples of VT patients totalling 951 subjects typed for 472 173 single nucleotide polymorphisms (SNPs), we observed that common SNPs explain 21% and 27% of the genetic variance of plasma AT and PS levels, even though no SNP reached genome-wide significance. For PC, we showed that two PROCR SNPs, rs867186 (Ser219Gly) and rs6060278, additionally explained c. 20% (P = 1·19 × 10(-31)) of the variance of plasma PC levels. We also observed that c. 40% of the remaining genetic variance of PC levels could be due to yet unidentified common SNPs. The PROCR locus was also found to explain c. 8% (P < 10(-10)) of agkistrodon contortrix venom (ACV) (exploring the PC pathway) variability which was under the main control of the F5 and F2 loci that further explained about 40% and 10%, respectively. We presented here the first GWAS for plasma AT and free-PS levels and ACV in Caucasian samples. We identified three independent loci associated with ACV (F2, F5 and PROCR) and replicated two independent effects on plasma PC levels at the PROCR locus.
Asunto(s)
Proteínas Antitrombina , Estudio de Asociación del Genoma Completo , Polimorfismo de Nucleótido Simple , Proteína C , Proteína S , Trombosis de la Vena , Adulto , Antígenos CD/genética , Proteínas Antitrombina/genética , Proteínas Antitrombina/metabolismo , Coagulación Sanguínea/efectos de los fármacos , Coagulación Sanguínea/genética , Venenos de Crotálidos/farmacología , Receptor de Proteína C Endotelial , Femenino , Sitios Genéticos , Humanos , Masculino , Persona de Mediana Edad , Proteína C/genética , Proteína C/metabolismo , Proteína S/genética , Proteína S/metabolismo , Receptores de Superficie Celular/genética , Estudios Retrospectivos , Factores de Riesgo , Trombosis de la Vena/sangre , Trombosis de la Vena/genéticaRESUMEN
Serine protease inhibitors, or serpins, are a group of widely distributed proteins with similar structures that use conformational change to inhibit proteases. Antithrombin (AT) is a member of the serine protease inhibitor superfamily and a major coagulation inhibitor in all vertebrates, but its evolutionary origin remains elusive. In this study we isolated for the first time a cDNA encoding an antithrombin homolog, BjATl, from the protochordate Branchiostoma japonicum. The deduced protein BjATl consisted of 338 amino acids sharing 36.7% to 41.1% identity to known vertebrate ATs. BjATl contains a potential N-linked glycosylation site, two potential heparin binding sites and the reactive center loop with the absolutely conserved sequence Gly-Arg-Ser; all of these are features characteristic of ATs. All three phylogenetic trees constructed using Neighbor-Joining, Maximum-Likelihood and Bayesian-Inference methods also placed BjATl together with ATs. Moreover, BjATl expressed in yeast cells was able to inhibit bovine thrombin activity by forming a SDS-stable BjATl-thrombin complex. It also displays a concentration-dependent inhibition of thrombin that is accelerated by heparin. Furthermore, BjATl was predominantly expressed in the hepatic caecum and hind-gut, agreeing with the expression pattern of AT in mammalian species. All these data clearly demonstrate that BjATl is an ortholog of vertebrate ATs, suggesting that a primitive coagulation system emerged in the protochordate.
Asunto(s)
Proteínas Antitrombina/genética , Evolución Biológica , Coagulación Sanguínea/genética , Cordados no Vertebrados/química , Filogenia , Serpinas/genética , Animales , Proteínas Antitrombina/metabolismo , Secuencia de Bases , Teorema de Bayes , Coagulación Sanguínea/fisiología , Bovinos , Cordados no Vertebrados/fisiología , ADN Complementario/genética , Funciones de Verosimilitud , Modelos Genéticos , Datos de Secuencia Molecular , Análisis de Secuencia de ADN , Homología de Secuencia , Serpinas/metabolismo , Especificidad de la Especie , Trombina/metabolismoRESUMEN
The natural anticoagulant protein S contains a so-called thrombin- sensitive region (TSR), which is susceptible to proteolytic cleavage. We have previously shown that a platelet-associated protease is able to cleave protein S under physiological plasma conditions in vitro . The aim of the present study was to investigate the relation between platelet-associated protein S cleaving activity and in vivo protein S cleavage, and to evaluate the impact of in vivo protein S cleavage on its anticoagulant activity. Protein S cleavage in healthy subjects and in thrombocytopenic and thrombocythaemic patients was evaluated by immunological techniques. Concentration of cleaved and intact protein S was correlated to levels of activated protein C (APC)-dependent and APC-independent protein S anticoagulant activity. In plasma from healthy volunteers 25% of protein S is cleaved in the TSR. While in plasma there was a clear positive correlation between levels of intact protein S and both APC-dependent and APC-independent protein S anticoagulant activities, these correlations were absent for cleaved protein S. Protein S cleavage was significantly increased in patients with essential thrombocythaemia (ET) and significantly reduced in patients with chemotherapy-induced thrombocytopenia. In ET patients on cytoreductive therapy, both platelet count and protein S cleavage returned to normal values. Accordingly, platelet transfusion restored cleavage of protein S to normal values in patients with chemotherapy-induced thrombocytopenia. In conclusion, proteases from platelets seem to contribute to the presence of cleaved protein S in the circulation and may enhance the coagulation response in vivo by down regulating the anticoagulant activity of protein S.
Asunto(s)
Proteínas Antitrombina/metabolismo , Plaquetas/metabolismo , Neoplasias Hematológicas/sangre , Fragmentos de Péptidos/metabolismo , Proteína S/metabolismo , Trombocitemia Esencial/sangre , Trombocitopenia/sangre , Proteínas Antitrombina/química , Proteínas Antitrombina/genética , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea , Plaquetas/patología , Dominio Catalítico/genética , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/tratamiento farmacológico , Humanos , Masculino , Fragmentos de Péptidos/química , Fragmentos de Péptidos/genética , Transfusión de Plaquetas , Proteína C/metabolismo , Procesamiento Proteico-Postraduccional/genética , Proteína S/química , Proteína S/genética , Proteolisis/efectos de los fármacos , Trombocitemia Esencial/prevención & control , Trombocitopenia/etiología , Trombocitopenia/prevención & controlRESUMEN
BACKGROUND: Inherited deficiency of antithrombin, protein C and protein S, three important, naturally occurring coagulation inhibitors, might play a major role in the occurrence of venous thromboembolism in Chinese. The establishment of age- and gender-related normal ranges of these inhibitors is crucial for an accurate diagnosis of these deficiencies. DESIGN AND METHODS: We designed a prospective cross-sectional study recruiting healthy adults from four university-affiliated hospitals in China. Antithrombin, protein C and protein S were studied by measuring their activity. Gene analysis was performed when natural anticoagulant deficiency was suspected. Polymorphisms of the factor V gene were searched for among subjects who were positive for activated protein C resistance. RESULTS: In 3493 healthy Chinese adults (1734 men, 1759 women; age 17-83 years), we found higher age-adjusted activities for protein C and protein S in men than in women but no sex difference for antithrombin. In women, mean protein C and protein S activities increased with age. In men, mean protein C levels increased with age up to the age of 49 but decreased after 50 years old; mean protein S levels decreased after 50 years of age. Antithrombin levels remained stable over time in women but decreased significantly after 50 years of age in men. Reference values according to age and sex allowed the identification of 15 genetic variants (protein C:10, antithrombin:3, protein S:2) in subjects with protein activity below the 1(st) percentile. CONCLUSIONS: This is the largest survey ever conducted in the healthy general Chinese population. These normal ranges provide the essential basis for the diagnosis and treatment of thrombosis in Chinese.
Asunto(s)
Proteínas Antitrombina/genética , Proteínas Antitrombina/metabolismo , Hemostasis/genética , Proteína C/genética , Proteína S/genética , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , China , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mutación/genética , Polimorfismo Genético , Proteína C/metabolismo , Proteína S/metabolismo , Valores de Referencia , Factores Sexuales , Adulto JovenRESUMEN
Histidine-rich protein II (HRPII) is an abundant protein released into the bloodstream by Plasmodium falciparum, the parasite that causes the most severe form of human malaria. Here, we report that HRPII binds tightly and selectively to coagulation-active glycosaminoglycans (dermatan sulfate, heparan sulfate, and heparin) and inhibits antithrombin (AT). In purified systems, recombinant HRPII neutralized the heparin-catalyzed inhibition of factor Xa and thrombin by AT in a Zn(2+)-dependent manner. The observed 50% inhibitory concentration (IC(50)) for the HRPII neutralization of AT activity is approximately 30nM for factor Xa inhibition and 90nM for thrombin inhibition. Zn(2+) was required for these reactions with a distribution coefficient (K(d)) of approximately 7µM. Substituting Zn(2+) with Cu(2+), but not with Ca(2+), Mg(2+), or Fe(2+), maintained the HRPII effect. HRPII attenuated the prolongation in plasma clotting time induced by heparin, suggesting that HRPII inhibits AT activity by preventing its stimulation by heparin. In the microvasculature, where erythrocytes infected with P falciparum are sequestered, high levels of released HRPII may bind cellular glycosaminoglycans, prevent their interaction with AT, and thereby contribute to the procoagulant state associated with P falciparum infection.
Asunto(s)
Antígenos de Protozoos/metabolismo , Proteínas Antitrombina/metabolismo , Malaria Falciparum/metabolismo , Plasmodium falciparum/metabolismo , Proteínas Protozoarias/metabolismo , Anticoagulantes/farmacología , Antígenos de Protozoos/química , Antígenos de Protozoos/genética , Proteínas Antitrombina/química , Proteínas Antitrombina/genética , Coagulación Sanguínea/efectos de los fármacos , Coagulación Sanguínea/genética , Factor Xa/química , Factor Xa/genética , Factor Xa/metabolismo , Heparina/farmacología , Humanos , Malaria Falciparum/genética , Metales/química , Metales/metabolismo , Plasmodium falciparum/genética , Plasmodium falciparum/inmunología , Proteínas Protozoarias/química , Proteínas Protozoarias/genéticaRESUMEN
MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs that are negative regulators in a crescent number of physiological and pathological processes. However, their role in haemostasis, a complex physiological process involving multitude of effectors, is just beginning to be characterized. We evaluated the changes of expression of miRNAs in livers of neonates (day one after birth) and adult mice by microarray and qRT-PCR trying to identify miRNAs that potentially may also be involved in the control of the dramatic change of hepatic haemostatic protein levels associated with this transition. Twenty one out of 41 miRNAs overexpressed in neonate mice have hepatic haemostatic mRNA as potential targets. Six of them identified by two in silico algorithms potentially bind the 3'UTR regions of F7, F9, F12, FXIIIB, PLG and SERPINC1 mRNA. Interestingly, miR-18a and miR-19b, overexpressed 5.4 and 8.2-fold respectively in neonates, have antithrombin, a key anti-coagulant with strong anti-angiogenic and anti-inflammatory roles, as a potential target. The levels of these two miRNAs inversely correlated with antithrombin mRNA levels during development (miR-19b: Râ=â0.81; pâ=â0.03; miR-18a: Râ=â0.91; p<0.001). These data suggest that miRNAs could be potential modulators of the haemostatic system involved in developmental haemostasis.